Page last updated: 2024-12-10

1,2-di-(heptacosadiynoyl)-sn-glycero-3-phosphocholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1,2-di-(heptacosadiynoyl)-sn-glycero-3-phosphocholine (Di-heptacosadiynoyl-PC)

This is a complex chemical name referring to a specific type of **phospholipid**. Let's break it down:

* **1,2-di-(heptacosadiynoyl)-:** This part describes the fatty acid chains attached to the glycerol backbone.
* **Heptacosadiynoyl:** This is a 27-carbon long fatty acid containing two triple bonds (indicated by di-ynoyl).
* **1,2-di-:** This indicates that two of these heptacosadiynoyl chains are attached to the first and second carbon positions of the glycerol molecule.

* **sn-glycero-3-phospho:** This part refers to the glycerol backbone with a phosphate group attached to the third carbon.

* **choline:** This is the head group of the phospholipid, attached to the phosphate group.

**In summary, Di-heptacosadiynoyl-PC is a phospholipid with two long, unsaturated fatty acid chains and a choline head group.**

## Importance in Research

Di-heptacosadiynoyl-PC is a very specific type of phospholipid that is **not found naturally**. It's important for research because it has several unique properties that make it a valuable tool for studying:

* **Membrane structure and dynamics:** Di-heptacosadiynoyl-PC's rigid structure and long fatty acid chains allow researchers to manipulate and study the physical properties of cell membranes, like fluidity and permeability.
* **Lipid signaling:** The unique structure of the fatty acid chains can influence how cells respond to various stimuli, providing insights into lipid signaling pathways.
* **Drug delivery:** The hydrophobic nature of the fatty acid chains makes Di-heptacosadiynoyl-PC a potential carrier for drugs that need to be delivered across cell membranes.
* **Biomaterial development:** The unique properties of this phospholipid can be utilized in the development of novel biomaterials for tissue engineering and drug delivery.

**In essence, Di-heptacosadiynoyl-PC serves as a model system for studying the role of phospholipids in biological systems. By altering its structure and properties, researchers can gain valuable insights into the mechanisms of cellular function and develop novel applications for this synthetic phospholipid.**

1,2-di-(heptacosadiynoyl)-sn-glycero-3-phosphocholine: RN given refers to (11,13-diyn)-isomer; RN for cpd without isomeric designation 8/89 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3081146
SCHEMBL ID9805716
MeSH IDM0160108

Synonyms (7)

Synonym
1,2-di-(heptacosadiynoyl)-sn-glycero-3-phosphocholine
118024-74-1
3,5,9-trioxa-4-phosphahexatriaconta-20,22-diyn-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxo-11,13-heptacosadiynyl)oxy)-, hydroxide, inner salt, 4-oxide, (r)-
dc8,9pc
[(2r)-2,3-di(heptacosa-11,13-diynoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
SCHEMBL9805716
DTXSID90152002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's1 (14.29)18.2507
2000's3 (42.86)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]